Brought to you by 
Bayer signs latest gene editing alliance with ERS Genomics
May 2016
Executive Summary
On the heels of its joint venture with CRISPR Therapeutics, Bayer AG signed another gene editing alliance, this time with ERS Genomics Ltd.
Deal Industry
- Research, Analytical Equipment & Supplies
Deal Status
- Final
Deal Type
-
Alliance
- R+D and Marketing-Licensing
Already a Strategic Transactions subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
Advertisement
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Bayer signs latest gene editing alliance with ERS Genomics
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice